Genmab's multiple myeloma drug wins fast-track status

04/4/2013 | RTT News

The FDA granted fast-track status to daratumumab, an experimental multiple myeloma drug being developed by Genmab and Janssen Biotech. The designation covers patients who already received at least three lines of treatments including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a PI and an IMiD, this article says.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI